ArticleCurrent oncology (Toronto, Ont.)2026
Maintenance Strategies in High-Risk Myeloma: A Multicenter Comparison of Bortezomib-Lenalidomide Versus Lenalidomide Alone: A USMIRC Multicenter Analysis.
Sruthi P Ramanan, Oyepeju F Abioye, Shebli Atrash, Jianzheng Wu, Dinesh Pal Mudaranthakam, Anita Mazloom, Omar Alkharabsheh, Mansi R Shah, Zahra Mahmoudjafari, Jordan Snyder and 5 more
Abstract readMulticenter StudyComparative Study
In one paragraphArticle in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Sruthi P RamananDivision of Hematology and Cellular Therapy, AHN Cancer Institute, Allegheny Health Network, Pittsburgh, PA 15212, USA.ORCID 0000-0001-9140-0189 Oyepeju F AbioyeDivision of Hematology and Cellular Therapy, AHN Cancer Institute, Allegheny Health Network, Pittsburgh, PA 15212, USA.ORCID 0000-0003-2266-2120 Shebli AtrashLevine Cancer Center, Atrium Health, Wake Forest University School of Medicine, Charlotte, NC 28204, USA.ORCID 0000-0003-4547-7534 Jianzheng WuDepartment of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS 66103, USA.
Dinesh Pal MudaranthakamDepartment of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS 66103, USA.ORCID 0000-0001-9767-1158 Anita MazloomDivision of Hematology and Oncology, Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.ORCID 0009-0009-7899-7078 Omar AlkharabshehDivision of Hematology and Oncology, Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.ORCID 0000-0002-5299-4233 Mansi R ShahDivision of Blood Disorders, Rutgers Cancer Institute, New Brunswick, NJ 08903, USA.
Zahra MahmoudjafariDivision of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS 66205, USA.ORCID 0000-0002-3168-2521 Jordan SnyderDivision of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS 66205, USA.
Muhammad Umair MushtaqDivision of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS 66205, USA.
Forat LutfiDivision of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS 66205, USA.ORCID 0000-0002-9699-3080 Jeries KortDivision of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS 66205, USA.
Al-Ola AbdallahDivision of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS 66205, USA.ORCID 0000-0002-6603-185X Prerna MewawallaDivision of Hematology and Cellular Therapy, AHN Cancer Institute, Allegheny Health Network, Pittsburgh, PA 15212, USA.ORCID 0009-0008-7464-6898 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Antineoplastic Combined Chemotherapy ProtocolsBortezomibLenalidomideMultiple MyelomaAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesBortezomibLenalidomidebortezomibdoublet maintenancehigh-risk multiple myelomalenalidomidepost-ASCT maintenance
Identifiers
PMID41892192
PMCPMC13025574
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390